Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catalyst Bio (CBIO)

Catalyst Bio (CBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Company News For Oct 4, 2019

Companies in the news are: STZ, BBBY, PEP, CBIO

STZ : 197.02 (-0.14%)
PEP : 136.25 (-0.52%)
BBBY : 12.53 (-0.40%)
CGC : 20.21 (-2.65%)
CBIO : 5.38 (-4.10%)
Catalyst Biosciences Provides DalcA Phase 2b Trial Update

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX)...

CBIO : 5.38 (-4.10%)
22NW: Catalyst Biosciences Needs Change Now

Dear Catalyst Biosciences, Inc. Shareholders:

CBIO : 5.38 (-4.10%)
Catalyst Biosciences Enters Oversold Territory

Catalyst Biosciences, Inc. (CBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

CBIO : 5.38 (-4.10%)
22NW: Catalyst Biosciences Needs Change Now

Dear Catalyst Biosciences, Inc. Shareholders:

CBIO : 5.38 (-4.10%)
22NW: Catalyst Biosciences Needs Change Now

Dear Catalyst Biosciences, Inc. Shareholders:

CBIO : 5.38 (-4.10%)
Catalyst Biosciences to Present at the Cantor Global Healthcare Conference

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Cantor 2019...

CBIO : 5.38 (-4.10%)
Catalyst Biosciences to Present at the 2019 ASBMB Symposium on Serine Proteases in Pericellular Proteolysis and Signaling Conference

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the 2019 American Society for Biochemistry and Molecular Biology (ASBMB) Symposium on Serine Proteases in Pericellular...

CBIO : 5.38 (-4.10%)
Catalyst Biosciences Announces Transition of Chief Financial Officer

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from the Company to pursue another opportunity effective August 30, 2019....

CBIO : 5.38 (-4.10%)
Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the Second Annual 2019 Hemophilia Drug Development (HDD) Summit being held from August 20-22, 2019 in Boston.

CBIO : 5.38 (-4.10%)
Catalyst Biosciences to Host Key Opinion Leader Meeting on Next-Generation Subcutaneous Factor VIIa Marzeptacog Alfa (Activated) in Patients with Bleeding Disorders on August 15

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that it will host a Key Opinion Leader (KOL) meeting on next-generation subcutaneous Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA)...

CBIO : 5.38 (-4.10%)
Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update

Phase 2 trial of subcutaneously administered MarzAA met primary endpoint of reduction in annualized bleed rate demonstrating safety and clinical efficacy, with >90% reduction in bleeding

CBIO : 5.38 (-4.10%)
Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors

Subcutaneous MarzAA (FVIIa) prophylaxis reduced the annualized bleeding rate by more than 90% compared with pretreatment

CBIO : 5.38 (-4.10%)
Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis

Oral presentation of the final Phase 2 trial data of MarzAA for the treatment of hemophilia A or B with inhibitors

CBIO : 5.38 (-4.10%)
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update

Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019

CBIO : 5.38 (-4.10%)
Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

A single intravitreal injection of 125 μg CB 2782-PEG achieved complete, rapid and sustained pharmacodynamic inhibition (>99%) of complement factor 3 (C3) in non-human primates (NHP), supporting dosing...

CBIO : 5.38 (-4.10%)
New Research: Key Drivers of Growth for CBRE Group, Brookfield Asset Management, Zebra Technologies, Trex, Catalyst Biosciences, and Albireo Pharma -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CBRE Group, Inc. (NYSE:CBRE),...

CBRE : 52.21 (-0.27%)
BAM : 53.37 (-0.04%)
ZBRA : 203.06 (-1.30%)
TREX : 90.85 (+0.41%)
CBIO : 5.38 (-4.10%)
ALBO : 17.61 (-1.51%)
Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference

Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Needham & Company 18th Annual Healthcare...

CBIO : 5.38 (-4.10%)
Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B

Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX)...

CBIO : 5.38 (-4.10%)
Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)

Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that the European Commission has awarded orphan designation of its Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for the treatment...

CBIO : 5.38 (-4.10%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +4.48 , AIZ -0.27 , SBAC +4.06 , SO +0.08 , WELL +0.91
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar